Mitochondrial DNA efflux as a potential amplifier of systemic inflammatory network rewiring in heart failure with preserved ejection fraction - Scorecard - MDSpire
Advertisement
Mitochondrial DNA efflux as a potential amplifier of systemic inflammatory network rewiring in heart failure with preserved ejection fraction
Clinical Scorecard: Mitochondrial DNA Release as a Potential Enhancer of Systemic Inflammatory Network Alterations in Heart Failure with Preserved Ejection Fraction
At a Glance
Category
Detail
Condition
Heart Failure with Preserved Ejection Fraction (HFpEF)
Key Mechanisms
Mitochondrial DNA (mtDNA) acts as a damage-associated molecular pattern and systemic inflammatory signal, linking comorbid stress factors with inflammation and organ dysfunction.
Target Population
Patients with Heart Failure with Preserved Ejection Fraction, particularly those with comorbidities such as aging, obesity, diabetes, hypertension, and renal dysfunction.
Care Setting
Clinical settings addressing systemic inflammatory diseases and heart failure management.
Key Highlights
HFpEF is characterized by a systemic inflammatory response affecting multiple organs.
mtDNA can be released in various forms, serving as a potential inflammatory signal.
Activation of TLR9 and cGAS-STING pathways by mtDNA contributes to inflammation.
mtDNA release may amplify endothelial dysfunction and myocardial remodeling.
The role of mtDNA in HFpEF is complex and varies by phenotype and disease stage.
Guideline-Based Recommendations
Diagnosis
Consider systemic inflammation and comorbidities in the assessment of HFpEF.
Management
Focus on managing comorbidities that contribute to systemic inflammation in HFpEF.
Monitoring & Follow-up
Monitor inflammatory markers and mtDNA levels as potential indicators of disease progression.
Risks
Increased risk of multi-organ dysfunction due to persistent inflammation in HFpEF.
Patient & Prescribing Data
Individuals diagnosed with HFpEF and associated comorbidities.
Management strategies should address both heart failure symptoms and underlying inflammatory processes.
Clinical Best Practices
Integrate assessment of systemic inflammation in the management of HFpEF.
Utilize a multidisciplinary approach to address comorbidities in HFpEF patients.
Consider the role of mitochondrial dysfunction in the pathophysiology of HFpEF.
